Caspofungin is an antifungal medication used to treat invasive fungal infections. Recent reports have indicated that its effectiveness may be reduced when polyacrylonitrile (PAN) membranes are used during continuous renal replacement therapy (CRRT).

In these conditions, the membrane may absorb some of the drug, reducing its concentration in the blood and making the treatment less effective. This may lead to therapeutic failure and worsening of the infection, potentially with serious outcomes.

To ensure maximum effectiveness of the treatment, it is recommended to avoid the use of PAN membranes during CRRT and to consider alternative membranes or antifungal agents, based on clinical judgement.

The product information for medicines containing caspofungin will be updated to inform healthcare professionals about the potential risk of drug sequestration.

Reporting suspected adverse reactions is essential for monitoring drug safety and protecting patient health.